Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension

• Published in: Journal of human hypertension Vol. 35; no. 8; pp. 709 - 717
• Main Authors: Chedier, Bernardo, Cortez, Arthur Fernandes, Roderjan, Christian Nejm, Cavalcanti, Aline de Hollanda, Carlos, Fernanda Oliveira de Carvalho, dos Santos, Bruno Dussoni Moreira, Muxfeldt, Elizabeth Silaid
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01.08.2021
• Subjects: Antihypertensives; Aorta; Blood pressure; Cardiovascular diseases; Drug resistance; Drug therapy; Heart; Hypertension; Hypertrophy; Patient outcomes; Patients; Phenotypes; Risk factors; Spironolactone; Statistical analysis; Statistics; Vascular diseases; Ventricle; Brazil
• ISSN: 0950-9240; 1476-5527
• DOI: 10.1038/s41371-020-00406-2

Refractory hypertension (RfHT) is an extreme phenotype of resistant hypertension (RHT) and is considered uncontrolled blood pressure (BP) despite the use of five or more antihypertensives. The objective of this study was to characterize the prevalence and clinical profile of RfHT patients in a historical cohort of patients with RHT at two different times: before and after the introduction of spironolactone. First, this cross-sectional study evaluated 1048 RHT patients (72.3% females, mean [SD] age: 61.2 [11.3] years) referred to a hypertension clinic (prespironolactone period). All patients were submitted to a standard protocol including clinical and complementary exams. Second, the analysis evaluated patients after the introduction of spironolactone (postspironolactone period). Statistical analysis included bivariate comparisons between patients with RHT and patients with RfHT and logistic regressions to assess the independent correlations of RfHT. A total of 146 patients (13.9%) remained refractory despite the use of at least five antihypertensives (prespironolactone period). After the introduction of spironolactone, the prevalence increased to 17.6%. For any criterion, RfHT patients were younger and more obese. In the initial period, current smoking and left ventricular hypertrophy were independently correlated with RfHT. Furthermore, after spironolactone use, RfHT patients had lower aortic stiffness and peripheral artery disease (PAD), pointing to a lower cardiovascular risk despite the lack of BP control. Younger age and lower prevalence of PAD correlated independently with RfHT. In conclusion, there was a high prevalence of RfHT, especially in younger and obese patients, and spironolactone use seemed to reduce cardiovascular risk despite the lack of BP control.